EA015569B1 - Бензотиазолы, обладающие антагонистической активностью по отношению к h3-рецептору гистамина, и фармацевтические композиции, включающие эти соединения - Google Patents

Бензотиазолы, обладающие антагонистической активностью по отношению к h3-рецептору гистамина, и фармацевтические композиции, включающие эти соединения Download PDF

Info

Publication number
EA015569B1
EA015569B1 EA200870376A EA200870376A EA015569B1 EA 015569 B1 EA015569 B1 EA 015569B1 EA 200870376 A EA200870376 A EA 200870376A EA 200870376 A EA200870376 A EA 200870376A EA 015569 B1 EA015569 B1 EA 015569B1
Authority
EA
Eurasian Patent Office
Prior art keywords
mmol
benzothiazole
mixture
isopropylpiperazin
cyclopropylpiperazin
Prior art date
Application number
EA200870376A
Other languages
English (en)
Russian (ru)
Other versions
EA200870376A1 (ru
Inventor
Флоренсио Сарагоса Дервальд
Кнуд Эрик Андерсен
Рольф Хольвег
Инге Тогер Кристенсен
Яне Мари Лундбекк
Original Assignee
ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи filed Critical ХАЙ ПОЙНТ ФАРМАСЬЮТИКАЛЗ, ЭлЭлСи
Publication of EA200870376A1 publication Critical patent/EA200870376A1/ru
Publication of EA015569B1 publication Critical patent/EA015569B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58—Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Otolaryngology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Nutrition Science (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Child & Adolescent Psychology (AREA)
EA200870376A 2006-03-28 2007-03-22 Бензотиазолы, обладающие антагонистической активностью по отношению к h3-рецептору гистамина, и фармацевтические композиции, включающие эти соединения EA015569B1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP06111820 2006-03-28
US78747806P 2006-03-30 2006-03-30
EP06112425 2006-04-10
US79428806P 2006-04-21 2006-04-21
EP06026875 2006-12-24
US90350307P 2007-02-26 2007-02-26
PCT/EP2007/052751 WO2007110364A1 (en) 2006-03-28 2007-03-22 Benzothiazoles having histamine h3 receptor activity

Publications (2)

Publication Number Publication Date
EA200870376A1 EA200870376A1 (ru) 2009-04-28
EA015569B1 true EA015569B1 (ru) 2011-10-31

Family

ID=43124961

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870376A EA015569B1 (ru) 2006-03-28 2007-03-22 Бензотиазолы, обладающие антагонистической активностью по отношению к h3-рецептору гистамина, и фармацевтические композиции, включающие эти соединения

Country Status (15)

Country Link
US (2) US8394842B2 (enExample)
EP (1) EP1999120B1 (enExample)
JP (1) JP2009531376A (enExample)
KR (1) KR101280333B1 (enExample)
CN (1) CN101410385B (enExample)
AU (1) AU2007229492B2 (enExample)
CA (1) CA2645581A1 (enExample)
EA (1) EA015569B1 (enExample)
ES (1) ES2388681T3 (enExample)
IL (1) IL193441A0 (enExample)
MX (1) MX2008011123A (enExample)
NZ (1) NZ570524A (enExample)
SG (1) SG170785A1 (enExample)
WO (1) WO2007110364A1 (enExample)
ZA (1) ZA200806985B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030236259A1 (en) * 2002-02-05 2003-12-25 Rolf Hohlweg Novel aryl- and heteroarylpiperazines
MX2007015675A (es) * 2005-07-04 2008-02-20 Novo Nordisk As Antagonistas del receptor de histamina h3.
CA2653062A1 (en) * 2006-05-23 2007-11-29 Transtech Pharma, Inc. 6- (4-cyclopropylpiperazin-1-yl) -2 ' -methyl- [3, 4 ' ] -bipyridine and its use as a medicament
CN102295606A (zh) * 2006-05-29 2011-12-28 高点制药有限责任公司 合成3-（1，3-苯并间二氧杂环戊烯-5-基）-6-（4-环丙基哌嗪-1-基）-哒嗪的方法及其适用的中间体
EP2014656A3 (en) * 2007-06-11 2011-08-24 High Point Pharmaceuticals, LLC New heteocyclic h3 antagonists
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US8153813B2 (en) * 2007-12-20 2012-04-10 Abbott Laboratories Benzothiazole and benzooxazole derivatives and methods of use
BRPI0924844A2 (pt) * 2009-03-24 2016-01-26 Sanofi Sa derivados de azacarbolinas 9h-pirrol[2,3-b:5,4-c']dipiridina, sua preparação e sua utilização terapêutica.
US8481547B2 (en) * 2009-12-18 2013-07-09 Janssen Pharmaceutica Nv Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1
PT2611444E (pt) * 2010-09-02 2016-02-04 Suven Life Sciences Ltd Compostos heterociclilo como ligandos de recetores de histamina h3
EP2683700B1 (de) 2011-03-08 2015-02-18 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120055A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
CN103958495B (zh) 2011-06-09 2018-06-22 理森制药股份公司 作为gpr-119的调节剂的化合物
TWI650321B (zh) * 2011-10-14 2019-02-11 美商安比特生物科學公司 雜環化合物及其使用方法
AU2014279240A1 (en) * 2013-06-10 2016-01-07 Astellas Pharma Inc. Bicyclic nitrogen-containing aromatic heterocyclic amide compound
KR20180014832A (ko) 2015-06-22 2018-02-09 액테리온 파마슈티칼 리미티드 Nadph 옥시다제 4 억제제
CN116199700A (zh) * 2016-03-11 2023-06-02 Ac免疫有限公司 用于诊断和治疗的双环化合物
CN106588808A (zh) * 2017-02-26 2017-04-26 长沙深橙生物科技有限公司 一种苯并[d]恶唑衍生物的制备方法
EP4151627A1 (en) 2017-06-05 2023-03-22 PTC Therapeutics, Inc. Compounds for treating huntington's disease
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
CN112805280B (zh) * 2018-06-27 2024-12-06 Ptc医疗公司 用于治疗亨廷顿氏病的杂芳基化合物
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
KR102682408B1 (ko) * 2021-05-12 2024-07-05 에이치케이이노엔 주식회사 신규한 벤조티아졸 유도체, 이의 제조방법 및 이의 간질환 예방 또는 치료 용도

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825407A1 (de) * 1977-06-10 1978-12-14 Science Union & Cie Piperazindithiocarbonsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
JPH02306916A (ja) * 1989-05-22 1990-12-20 Otsuka Pharmaceut Co Ltd 血小板粘着抑制剤
JPH04316565A (ja) * 1991-04-16 1992-11-06 Meiji Seika Kaisha Ltd 新規ベンゾチアゾール誘導体
JPH11199573A (ja) * 1998-01-07 1999-07-27 Yamanouchi Pharmaceut Co Ltd ５ｈｔ３受容体作動薬及び新規ベンゾチアゾール誘導体
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
EP1134220A1 (en) * 1998-11-20 2001-09-19 Meiji Seika Kaisha Ltd. Benzoxazole derivatives and drugs containing the same as the active ingredient
WO2002014271A1 (en) * 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Proline derivatives and use thereof as drugs
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
WO2003066604A2 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
WO2004101559A1 (en) * 2003-05-07 2004-11-25 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands
US20050059663A1 (en) * 2003-03-12 2005-03-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO156497C (no) 1984-10-18 1987-09-30 Helge Boe Anordning for sammenfoeyning av to plateformede elementer.
DE3511110A1 (de) 1985-03-27 1986-10-02 Dr. Karl Thomae Gmbh, 7950 Biberach Neue pyridazinone, ihre herstellung und diese verbindungen enthaltende arzneimittel
PH25772A (en) 1985-08-30 1991-10-18 Novo Industri As Insulin analogues, process for their preparation
FI91859C (fi) 1987-06-17 1994-08-25 Eisai Co Ltd Analogiamenetelmä antiallergisena aineena aktiivisen bentsotiatsolijohdannaisen valmistamiseksi
DE3837825A1 (de) 1988-11-08 1990-05-10 Hoechst Ag Neue insulinderivate, ihre verwendung und eine sie enthaltende pharmazeutische zubereitung
DE4223589A1 (de) 1992-07-17 1994-01-20 Fluehs Drehtechnik Gmbh Ventiloberteil
WO1994022846A1 (en) 1993-03-30 1994-10-13 Pfizer Inc. Compounds enhancing antitumor activity of other cytotoxic agents
JP3193560B2 (ja) 1993-04-16 2001-07-30 明治製菓株式会社 新規ベンゾオキサゾール誘導体
DE10199011I2 (de) 1993-06-21 2004-10-14 Novo Nordisk As ASP-B28-Insulinkristalle.
RU2164520C2 (ru) 1993-09-17 2001-03-27 Ново Нордиск А/С Производное инсулина, растворимая пролонгированная фармацевтическая композиция, способ пролонгирования гипогликемического действия при лечении диабета
US5504188A (en) 1994-06-16 1996-04-02 Eli Lilly And Company Preparation of stable zinc insulin analog crystals
CA2241567A1 (en) 1996-01-17 1997-07-24 Novo Nordisk A/S Fused 1,2,4-thiadiazine and fused 1,4-thiazine derivatives, their preparation and use
JP3520177B2 (ja) 1996-05-09 2004-04-19 明治製菓株式会社 セロトニン５−ｈｔ３受容体部分活性薬
EP0923580A1 (en) 1996-07-26 1999-06-23 Dr. Reddy's Research Foundation Thiazolidinedione compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions thereof
DK0944648T3 (da) 1996-08-30 2007-07-02 Novo Nordisk As GLP-1 derivater
DE69723869T2 (de) 1996-12-31 2004-04-22 Dr. Reddy's Laboratories Ltd. Heterozyklische verbindungen, verfahren zu ihrer herstellung, pharmazeutische zusammensetzungen die diese enthalten und ihre anwendung in der behandlung von diabetis und verwandten krankheiten
WO1997041119A1 (en) 1997-05-02 1997-11-06 Dr. Reddy's Research Foundation Novel antidiabetic compounds having hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
US6613942B1 (en) 1997-07-01 2003-09-02 Novo Nordisk A/S Glucagon antagonists/inverse agonists
AU749271B2 (en) 1997-07-01 2002-06-20 Agouron Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
PL338013A1 (en) 1997-07-16 2000-09-25 Novo Nordisk As Derivatives of condensed 1,2,4-thiadiazine, their production and application
EP0927992A4 (en) 1997-07-17 1999-09-15 Sony Corp MAGNETIC RECORDING MEDIUM AND MAGNETIC RECORDING / REPRODUCING DEVICE COMPRISING SAME
EE200000289A (et) 1997-10-27 2001-06-15 Agouron Pharmaceuticals, Inc. Asendatud 4-amino-tiasool-2-üüli ühendid kui tsükliinisõltuvusega kinaaside inhibiitorid
WO1999019313A1 (en) 1997-10-27 1999-04-22 Dr. Reddy's Research Foundation Novel tricyclic compounds and their use in medicine; process for their preparation and pharmaceutical compositions containing them
US6440961B1 (en) 1997-10-27 2002-08-27 Dr. Reddy's Research Foundation Tricyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
EP0971917B1 (en) 1997-12-02 2002-02-06 Dr. Reddy's Research Foundation Thiazolidinedione and oxazolidinedione derivatives having antidiabetic, hypolipidaemic and antihypertensive properties
JP2002527516A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物、それらの製造及び使用
EP1123267A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
WO2000023451A1 (en) 1998-10-21 2000-04-27 Novo Nordisk A/S New compounds, their preparation and use
JP2002527507A (ja) 1998-10-21 2002-08-27 ノボ ノルディスク アクティーゼルスカブ 新規化合物類、それらの調製及び使用
EP1123268A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
EP1123269A1 (en) 1998-10-21 2001-08-16 Novo Nordisk A/S New compounds, their preparation and use
AU1045300A (en) 1998-11-17 2000-06-05 Bayer Aktiengesellschaft Novel heterocyclyl-substituted oxazolidone derivatives
EP1338600A1 (en) 1998-12-18 2003-08-27 Novo Nordisk A/S Fused 1,2,4-Thiadiazine derivatives, their preparation and use
WO2000041121A1 (en) 1999-01-07 2000-07-13 Ccrewards.Com Method and arrangement for issuance and management of digital coupons and sales offers
AU3033500A (en) 1999-01-15 2000-08-01 Agouron Pharmaceuticals, Inc. Non-peptide glp-1 agonists
EE200100529A (et) 1999-04-16 2002-12-16 Dr. Reddy's Research Foundation Diabeedivastase agensi uudsed polümorfsed vormid:nende valmistamismeetod ja neid sisaldavad farmatseutilised kompositsioonid
WO2000063193A1 (en) 1999-04-16 2000-10-26 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
AU2953699A (en) 1999-04-16 2000-11-02 Dr. Reddy's Research Foundation Novel polymorphic forms of an antidiabetic agent: process for their preparation and a pharmaceutical composition containing them
JP2002542237A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造及び使用
AU3958100A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
AU3958200A (en) 1999-04-20 2000-11-02 Novo Nordisk A/S New compounds, their preparation and use
JP2002542218A (ja) 1999-04-20 2002-12-10 ノボ ノルディスク アクティーゼルスカブ 新規な化合物、それらの製造および使用
GB0003254D0 (en) 2000-02-11 2000-04-05 Darwin Discovery Ltd Heterocyclic compounds and their therapeutic use
ATE430730T1 (de) 2000-03-31 2009-05-15 Ortho Mcneil Pharm Inc Phenyl-substituierte indole als h3 histaminrezeptorantagonisten
AU2001251083A1 (en) 2000-03-31 2001-10-15 Ortho-Mcneil Pharmaceutical, Inc. Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists
US7576084B2 (en) 2001-10-12 2009-08-18 Choongwae Pharma Corporation Reverse-turn mimetics and method relating thereto
TW200538433A (en) 2004-02-24 2005-12-01 Irm Llc Immunosuppressant compounds and compositiions
SG165417A1 (en) 2005-09-23 2010-10-28 Memory Pharm Corp Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2825407A1 (de) * 1977-06-10 1978-12-14 Science Union & Cie Piperazindithiocarbonsaeurederivate, verfahren zu ihrer herstellung und sie enthaltende arzneimittel
JPH02306916A (ja) * 1989-05-22 1990-12-20 Otsuka Pharmaceut Co Ltd 血小板粘着抑制剤
JPH04316565A (ja) * 1991-04-16 1992-11-06 Meiji Seika Kaisha Ltd 新規ベンゾチアゾール誘導体
US6130217A (en) * 1995-09-20 2000-10-10 Pfizer Inc Compounds enhancing antitumor activity of other cytotoxic agents
JPH11199573A (ja) * 1998-01-07 1999-07-27 Yamanouchi Pharmaceut Co Ltd ５ｈｔ３受容体作動薬及び新規ベンゾチアゾール誘導体
EP1134220A1 (en) * 1998-11-20 2001-09-19 Meiji Seika Kaisha Ltd. Benzoxazole derivatives and drugs containing the same as the active ingredient
WO2002014271A1 (en) * 2000-08-10 2002-02-21 Mitsubishi Pharma Corporation Proline derivatives and use thereof as drugs
US20030073672A1 (en) * 2001-09-05 2003-04-17 Breitenbucher J. Guy Method for treating allergies using substituted pyrazoles
WO2003066604A2 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
US20050059663A1 (en) * 2003-03-12 2005-03-17 Kudos Pharmaceuticals Limited Phthalazinone derivatives
WO2004101559A1 (en) * 2003-05-07 2004-11-25 Abbott Laboratories Fused bicyclic-substituted amines as histamine-3 receptor ligands

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
CELANIRE ET AL.: "Keynote review: Histamine H3 receptor antagonists reach out for the clinic" DDT - DRUG DISCOVERY TODAY, ELSEVIER SCIENCE LTD., GB, vol. 10, no. 23-24, December 2005 (2005-12), pages 1613-1627, XP005222014 ISSN: 1359-6446 cited in the application the whole document *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IWAOKA, KIYOSHI ET AL.: "Benzothiazoles and 5-NT3 receptor agonists containing them" XP002396638 retrieved from STN Database accession no. 1999:463258 cited in the application abstract & JP 11199573 A2 (YAMANOUCHI PHARMACEUTICAL CO., LTD., JAPAN) 27 July 1999 (1999-07-27) *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; KITAJIMA, HIROSHI ET AL.: "Preparation of proline derivatives as dipeptidyl peptidase IV (DPP-IV) inhibitors and use thereof as drugs" XP002396637 retrieved from STN Database accession no. 2002:142666 abstract & WO 02/14271 Al (WELFIDE CORPORATION, JAPAN) 21 February 2002 (2002-02-21) *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; NISH1, TAKAO ET AL.: "Preparation of benzothiazoles and benzimidazoles as blood platelet aggregation inhibitors" XP002396639 retrieved from STN Database accession no. 1991:207259 abstract & JP 02306916 A2 (OTSUKA PHARMACEUTICAL CO., LTD., JAPAN) 20 December 1990 (1990-12-20) *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; SATO, YASUO ET AL.: "Preparation of benzothiazoles as cardiotonics" XP002396640 retrieved from STN Database accession no. 1993:161060 cited in the application abstract & JP 04316565 A2 (MEIJI SEIKA KAISHA, LTD., JAPAN) 6 November 1992 (1992-11-06) *
SATO Y. ET AL.: "Benzoxazole Derivatives as Novel 5-HT3 Receptor Partial Agonists in the Gut" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 41, no. 16, 1998, pages 3015-3021, XP002180160 ISSN: 0022-2623 the whole document *
YAMADA M. ET AL.: "A new 5-HT3 receptor ligand. II. Structure-activity analysis of 5-HT3 receptor agonist action in the gut" CHEMICAL AND PHARMACEUTICAL BULLETIN, PHARMACEUTICAL SOCIETY OF JAPAN, TOKYO, JP, vol. 46, no. 3, 1998, pages 445-451, XP002403658 ISSN: 0009-2363 the whole document *
YOSHIDA, SATOSHI ET AL.: "Orally Active Benzoxazole Derivative as 5-HT3 Receptor Partial Agonist for Treatment of Diarrhea-Predominant Irritable Bowel Syndrome" JOURNAL OF MEDICINAL CHEMISTRY, 48(22), 7075-7079 CODEN: JMCMAR; ISSN: 0022-2623, 2005, XP002437776 the whole document *

Also Published As

Publication number Publication date
KR101280333B1 (ko) 2013-07-02
NZ570524A (en) 2011-08-26
MX2008011123A (es) 2008-09-30
US8394842B2 (en) 2013-03-12
CN101410385B (zh) 2011-08-24
AU2007229492B2 (en) 2011-11-03
SG170785A1 (en) 2011-05-30
EA200870376A1 (ru) 2009-04-28
EP1999120B1 (en) 2012-06-27
AU2007229492A1 (en) 2007-10-04
CA2645581A1 (en) 2007-10-04
CN101410385A (zh) 2009-04-15
WO2007110364A1 (en) 2007-10-04
US20100298316A1 (en) 2010-11-25
US20130079340A1 (en) 2013-03-28
KR20080104042A (ko) 2008-11-28
US8772285B2 (en) 2014-07-08
HK1129102A1 (en) 2009-11-20
ES2388681T3 (es) 2012-10-17
EP1999120A1 (en) 2008-12-10
JP2009531376A (ja) 2009-09-03
ZA200806985B (en) 2010-12-29
IL193441A0 (en) 2009-05-04

Similar Documents

Publication Publication Date Title
EA015569B1 (ru) Бензотиазолы, обладающие антагонистической активностью по отношению к h3-рецептору гистамина, и фармацевтические композиции, включающие эти соединения
JP5121707B2 (ja) 新規医薬
US8344001B2 (en) Heterocyclic H3 antagonists
KR101487813B1 (ko) 11-베타-히드록시스테로이드 탈수소효소의 억제제로서 ｎ-아다만틸 벤즈아미드
JP2010519242A (ja) 新規化合物
EP2452937A1 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
US20120184544A1 (en) Substituted benzamide derivatives as glucokinase (gk) activators
HK1129102B (en) Benzothiazoles having histamine h3 receptor activity
BRPI0709187A2 (pt) benzotiazóis tendo atividade no receptor h3 de histamina
US20090076064A1 (en) Compounds
HK1142230A (en) New heteocyclic h3 antagonists
AU2012244121A1 (en) Histamine H3 receptor antagonists

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU